Comparing the current results to its competitors, Clene Inc reported Revenue increase in the 2 quarter 2026 by 233.33 % year on year. The sales growth was above Clene Inc 's competitors' average revenue growth of 11.08 %, achieved in the same quarter.
Clene Inc , slower than the average decrease reported by the company's competitors of -27.27 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -27.27 %
June 21, 2024
Rett Syndrome is a rare, debilitating neurodevelopmental disorder that predominantly affects girls. It is caused by a mutation in the MECP2 gene, resulting in severe behavioral and physical symptoms. Currently, there are no effective treatments for Rett Syndrome, leaving patients and their families desperate for a solution.Clene s CNM-Au8 offers a glimmer of hope. CNM-Au8 is a nanotherapeutic agent that has shown immense promise in preclinical models, particularly in conditions affecting mitochondrial function. The drug is based on a patented gold nanocrystal technology platform designed to catalyze the function of vital enzymes responsible for energy production within the cells. This groundbreaking approach...
May 1, 2024
In a recent episode of the podcast From Lab to Launch, Rob Etherington, President, Director, and CEO of Clene Inc., explores the inspiring journey of his late-stage biopharmaceutical company. The discussion delves into the fascinating stories of founders, investors, scientists, engineers, and pioneers in the life sciences sector. This article aims to outline the key takeaways from the podcast and shed light on Clene Inc. s innovative approach in the pharmaceutical industry.Clene Inc.: A Clinical-Stage Biopharmaceutical Company:Clene Inc. (NASDAQ: CLNN) is a renowned clinical-stage biopharmaceutical company that focuses on the development and commercialization of novel nanoscale therapeutics for neurodegenera...
January 8, 2024
Clene Inc., a clinical-stage biopharmaceutical company dedicated to enhancing mitochondrial health and safeguarding neuronal function for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), has recently revealed ground-breaking findings from the long-term open label extension (LTE) of the VISIONARY-MS trial. The trial focused on individuals with stable relapsing multiple sclerosis (RMS), and the results offer substantial hope for patients grappling with these debilitating conditions.Visionary Study Yields Encouraging Three-Year Follow-Up DataClene s subsidiary, Clene Nanomedicine Inc., disclosed remarkable new data on the efficacy and safety...
December 21, 2023
Clene Reports Promising Results in the Treatment of ALS with CNM-Au8SALT LAKE CITY, Dec. 21, 2023 - Clene Inc. (Nasdaq: CLNN) and its subsidiary Clene Nanomedicine Inc., pioneers in the field of mitochondrial health and neuronal function preservation, have recently announced significant advancements in the treatment of amyotrophic lateral sclerosis (ALS) through their CNM-Au8 therapy. The positive findings come from the 12-month long-term open label extension (OLE) of the CNM-Au8 treatment arm in the HEALEY ALS Platform Trial. These novel results offer renewed hope to those suffering from this devastating neurodegenerative disease.ALS, also known as Lou Gehrig s disease, is a progressive condition that affec...
Wave Life Sciences Ltd is a biotechnology company focused on developing and commercializing nucleic acid therapies for rare genetic diseases. Their business model revolves around utilizing their proprietary chemistry platform to design and create custom-built, targeted medicines that can potentially address a wide range of genetic disorders. They aim to bring these therapies through preclinical and clinical development stages and ultimately deliver innovative treatments to patients in need.
Amicus Therapeutics Inc is a biopharmaceutical company that focuses on the development and commercialization of therapies for rare and orphan diseases.
Enanta Pharmaceuticals Inc's business model focuses on the research, development, and commercialization of innovative small molecule drugs targeting viral infections and liver diseases.
Emmaus Life Sciences Inc's business model revolves around the development and commercialization of innovative pharmaceutical products, with a focus on the treatment and management of rare diseases and conditions. They aim to bring these life-saving therapies to market by conducting research, obtaining regulatory approvals, and establishing partnerships with healthcare providers and stakeholders.
Curis Inc's business model revolves around the development and commercialization of innovative cancer therapies. They focus on discovering and advancing drug candidates targeting specific molecular pathways involved in cancer growth and survival. The company collaborates with pharmaceutical partners to conduct clinical trials and seek regulatory approval for their products.
Sources:
Clene Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Clene Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
